Steve Ubl, president and CEO of AdvaMed will leave his post at AdvaMed in the fall to serve as president and CEO of PhRMA.
Ubl shared the letter below with the AdvaMed Board of Directors on Friday, September 25, 2015.Continue reading
Category Archives: AZBio News
Insys Therapeutics In-Licenses Cannabinoid Inhalation Technology; ExpandsLeadership Team
Partnership Enhances the Position of Insys as Potential Leader in Synthetic Pharmaceutical CannabinoidsContinue reading
LIFE in the Fast Lane: How three Arizona biotech companies are setting the pace
Calimmune, Inc., HTG Molecular Diagnostics, Inc., and VisionGate, Inc. are picking up the pace and when they reach the finish line we all win.Continue reading
Dr. Dan Rudmann Joins Flagship Biosciences as VP of Program Development
Flagship Biosciences continues to expand its leadership position in pathology-focused tissue image analysis with the addition of Dr. Dan Rudmann as Vice President of Program Development.Continue reading
SynCardia Files S-1 with expected price range for IPO
SynCardia Systems has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The expected price range given in the filing was $10 to $12 for 2.5 million shares, with an overallotment option for an additional 375,000 shares. At the maximum price, the total offering is valued up to $34.5 million. According to the S-1, the company intends to list on the Nasdaq Global Market under the symbol TAHT. (Source: 24/7 Wall St.)Continue reading